Connor, Clark & Lunn Investment Management (CC&L)’s ENZON PHARMACEUTICALS INC ENZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q2 | – | Sell |
-572,321
| Closed | -$269K | – | 997 |
|
|
2016
Q1 | $269K | Hold |
572,321
| – | – | ﹤0.01% | 671 |
|
|
2015
Q4 | $389K | Buy |
572,321
+23,800
| +4% | +$16.2K | ﹤0.01% | 588 |
|
|
2015
Q3 | $532K | Buy |
548,521
+191,200
| +54% | +$185K | ﹤0.01% | 509 |
|
|
2015
Q2 | $429K | Buy |
357,321
+94,800
| +36% | +$114K | ﹤0.01% | 447 |
|
|
2015
Q1 | $278K | Buy |
262,521
+32,200
| +14% | +$34.1K | ﹤0.01% | 466 |
|
|
2014
Q4 | $251K | Buy |
230,321
+9,300
| +4% | +$10.1K | ﹤0.01% | 494 |
|
|
2014
Q3 | $239K | Hold |
221,021
| – | – | ﹤0.01% | 472 |
|
|
2014
Q2 | $245K | Sell |
221,021
-4,737
| -2% | -$5.25K | ﹤0.01% | 471 |
|
|
2014
Q1 | $257K | Buy |
225,758
+34,700
| +18% | +$39.5K | ﹤0.01% | 588 |
|
|
2013
Q4 | $235K | Buy |
191,058
+9,487
| +5% | +$11.7K | ﹤0.01% | 644 |
|
|
2013
Q3 | $314K | Buy |
181,571
+41,734
| +30% | +$72.2K | ﹤0.01% | 415 |
|
|
2013
Q2 | $295K | Buy |
+139,837
| New | +$295K | ﹤0.01% | 428 |
|